Biomerica (Biomerica) GF Value : $0.87 (As of May. 13, 2024)

View and export this data going back to 1978. Start your Free Trial

What is Biomerica GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-13), Biomerica's share price is $0.5975. Biomerica's GF Value is $0.87. Therefore, Biomerica's Price-to-GF-Value for today is 0.69.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Biomerica is Possible Value Trap, Think Twice.

Biomerica (NAS:BMRA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Biomerica's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.5975	/	0.87
	=	0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomerica GF Value Related Terms

Thank you for viewing the detailed overview of Biomerica's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomerica (Biomerica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

17571 Von Karman Avenue, Irvine, CA, USA, 92614

Website

https://www.biomerica.com

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.

Executives

John P. Kenny	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani	director, officer: Cheif Executive Officer	17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu	officer: Chief Financial Officer	12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri	director
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan	officer: Chief Financial Officer	114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio	officer: President-diagnostics	1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore	director, 10 percent owner, officer: Secretary	1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson	director	1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider	other: Greater than 5% holder	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The	other: Greater than 5% holder	7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm	director	1533 MONROVIA AVE., NEWPORT BEACH CA 92663